乌司奴单抗治疗克罗恩病的长期疗效与安全性:至治疗第二年
基于UNITI-1和UNITI-2研究,1281例患者进入IM-UNITI维持治疗,其中718例进入长期延伸期。乌司奴单抗90 mg每12周或每8周皮下注射可维持临床缓解至第92周,安全性事件与安慰剂相似,未观察到新的安全信号。
要点
- 乌司奴单抗90 mg每12周或每8周维持治疗至第92周,临床缓解率分别从77.4%降至72.6%和从84.1%降至74.4%。
- 第92周时,每12周组与每8周组临床缓解率相似,既往剂量调整组较低。
- 至第96周,不良事件、严重不良事件和严重感染发生率在安慰剂和乌司奴单抗组间相似,未观察到剂量效应。
核心结论
- 皮下注射乌司奴单抗可维持临床应答和缓解至第92周,未观察到新的安全信号。
研究设计与样本
- III期UNITI-1(TNF拮抗剂失败)和UNITI-2(传统治疗失败)研究共1281例患者进入IM-UNITI维持治疗,其中397例随机分配至乌司奴单抗90 mg每12周、每8周或安慰剂,884例为非随机患者。
- 完成44周治疗的患者可进入长期延伸期,不再进一步调整剂量;揭盲后安慰剂组患者停药。
- 共718例患者(全部接受治疗)进入长期延伸期,其中298例为随机患者,420例为非随机患者。
主要发现
- 718例患者中86.5%(621/718)完成第96周。
- 随机患者中,乌司奴单抗90 mg每12周组临床缓解比例从第44周的77.4%至第92周的72.6%,每8周组从84.1%至74.4%,既往剂量调整组从63.4%至53.5%。
- 第92周时,乌司奴单抗90 mg每12周组与每8周组临床缓解比例相似,既往剂量调整组较低。
- 第92周时,全部接受治疗每8周组(64.4%)和每12周组(64.3%)的临床缓解比例低于随机每8周组(74.4%)和每12周组(72.6%),但维持情况相似。
- 第0-96周,安慰剂组与乌司奴单抗组每百患者年的安全性事件相似:不良事件484.39 vs 447.76,严重不良事件19.24 vs 18.82,严重感染4.09 vs 4.02;未观察到剂量效应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In Phase 3 studies of ustekinumab, a fully human monoclonal IL-12/23p40 antibody approved for moderate-to-severe Crohn's disease, patients entered a long-term extension after completing 8 weeks of induction and 44 weeks of maintenance treatment. Efficacy through 92 weeks and safety through 96 weeks of IM-UNITI maintenance are reported. METHODS: UNITI-1 (TNF-antagonist failures) and UNITI-2 (conventional therapy failures) patients (N = 1281) entered IM-UNITI, including 397 ustekinumab intravenous induction responders randomised to subcutaneous ustekinumab 90 mg every 12 weeks, every 8 weeks, or placebo and 884 nonrandomised patients. Dose-adjustment to 90 mg every 8 weeks occurred in patients randomised to 90 mg every 12 weeks and placebo patients with loss of response (Weeks 8-32). All Week 44 completers could enter the long-term extension without further dose adjustment. Placebo patients discontinued following study unblinding. RESULTS: A total of 718 patients (all treated) entered the long-term extension (298 randomised and 420 not randomised). Overall, 86.5% (621/718) completed Week 96. The proportions of randomised patients in clinical remission were generally maintained from Week 44 through 92 in ustekinumab 90 mg every 12 weeks (77.4% to 72.6%), every 8 weeks (84.1% to 74.4%), and prior dose adjustment groups (63.4% to 53.5%). At Week 92, the proportions of patients in clinical remission were similar in the ustekinumab 90 mg every 12 weeks and every 8 weeks groups and lower in patients with prior dose adjustment. Proportions of patients in clinical remission at Week 92 for all treated every 8 weeks (64.4%) and every 12 weeks (64.3%) groups were lower than randomised every 8 weeks (74.4%) and every 12 weeks (72.6%) groups, but similarly maintained. Safety events (per hundred patient-years) were similar among all placebo and ustekinumab patients (Week 0-96), including adverse events (484.39 vs 447.76), serious adverse events (19.24 vs 18.82), and serious infections (4.09 vs 4.02). No dose effect was observed. CONCLUSIONS: Subcutaneous ustekinumab maintained clinical response and remission through Week 92. No new safety signals were observed. ClinicalTrials.gov number NCT01369355.
引用
- Sandborn WJ, Rutgeerts P, Gasink C, et al. Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. Aliment Pharmacol Ther. 2018. PMID: 29797519. doi:10.1111/apt.14794
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。